Purpose: Five-year survival rates were widely dispersed in pN2 non-small cell lung cancer (NSCLC). The present study aims to investigate the prognosis of patients with lymph node metastasis beyond lobe-specific mediastinal regions. Methods: A total of 654 pathologically proved N2-NSCLC patients were enrolled. All patients underwent a major pulmonary resection and radical mediastinal lymphadenectomy. Two separate groups were assigned according to the definition of lobe-specific nodal metastasis: Group LS (lobe-specific) and Group NLS (non-lobe-specific). Survival rates were calculated using Kaplan-Meier and Cox regression models. Results: There were 376 cases in Group LS and 278 cases in Group NLS. Univariate analyses showed that the risk factors of 5-year survival were operation type, MLN positivity ratio, nodal station, nodal zone, and LS/NLS metastasis. The 5-year survival among those in Group LS was significantly better than that of Group NLS (27.5% vs. 11.7%, p <0.0001). Multivariate analysis confirmed that the grouping method of LS/NLS and number of involved nodal zones were the most prominent risk factors for 5-year survival. Conclusion: Lymph node metastasis beyond lobe-specific lymph nodes is an independent risk factor of 5-year survival and is associated with worse prognoses for N2 NSCLC patients.
Introduction
Lymphatic drainage of non-small cell lung cancers (NSCLCs), according to general knowledge, follows a relatively fixed route. For upper lobe lung cancers, the most frequently involved has been the upper nodal zone (stations #2-4, #5-6), while for the lower lobes, inferior nodal zone (stations #7-9) involvement is more commonly seen. 1) Investigations of N2 cases showed that station 4R metastasis occurred in 68% cases of right upper lobe tumors, while 78% of cases indicated stations #5-6 in left upper lobe tumors and 65% for station 7 in middle-and lower lobe tumors. 2) Riquet, et al. even stated that 75.9% of direct lymph flow pathways from the upper lobe went to stations #2-4 in the right and 95.7% to stations #1-6 in the left, and more than 50% of direct pathways ran from the lower lobes (at right, plus middle lobe)
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into stations #7-9. 3) Lobe-specific mediastinal lymph nodes, a concept derived from the above observation, has therefore been proposed to describe the corresponding relationship between a specified mediastinal nodal zone and cancer-involving pulmonary lobe. 4) For clinically early stage lung cancers, radical lymph node dissection may then be reasonably omitted, since metastasis beyond these lobe-specific nodes has been especially uncommon. 5, 6) Several subsequent clinical trials have also verified that selective nodal dissection simply on these lobe-specific nodes offered similar survival compared to systematic lymphadenectomy. 7, 8) However, for stage-III (TxN2M0) lung cancers, the definition of the term "lobe-specific node" may have additional prognostic significance. Common sense holds that lymph dissemination to a side path may be associated with a wider range of lymphatic involvement. We therefore, hypothesize that lymph node metastasis beyond lobe-specific mediastinal regions, which is called as nonlobe-specific nodes in the present study, also predicts worse outcomes.
Patients and Methods
Approval for the study was obtained from the Ethics Committee of the Hospital.
Patients and operations
From September 2005 to September 2009, 817 cases were pathologically confirmed of pT1-4N2M0 non-small cell lung cancers in the Department of Thoracic Surgery at Shanghai Pulmonary Hospital. Exclusion criteria of present study were (1) metastatic pulmonary carcinomas or small cell lung cancers, (2) prior history of induction chemo-or radio-therapy, and (3) incomplete resection or exploratory thoracotomy. At stage pT1-4N2M0, 654 cases were finally enrolled for further analysis.
All of these patients had preoperative examinations to exclude remote metastasis, which included a chest computed tomography (CT) scan, abdominal CT or ultrasonography examinations, brain magnetic resonance imaging (MRI) scan, and whole-body bone scan. Fiberoptic bronchoscopy was performed routinely for all surgical candidates. Mediastinoscopy or endobronchial ultrasound-guided trans-bronchial needle aspiration (EBUS-TBNA) was performed for all suspected cN2 cases.
Major lung resections (either anatomic lobectomy, bi-lobectomies, sleeve lobectomies, or pneumonectomies) combined with radical mediastinal lymphadenectomy were performed for all enrolled cases as noted by Naruke, et al. and Izbicki, et al. 9, 10) All enrolled cases had complete resections, and the resection margins had been verified as negative by on-site frozen section examinations during operations. The final histopathological classification was based on the 1999 World Health Organization guideline. TNM staging was unified, according to the 7th edition of IASLC's system, before being subjected to subsequent statistical analysis. 11)
Grouping methods
Two separate groups were assigned according to the definition of lobe-specific nodal metastasis ( Table 1) . Patients with only lobe-specific mediastinal nodal metastasis were delineated into Group LS, and those with nodal metastasis beyond lobe-specific nodal zones were included in Group NLS (non-lobe-specific metastasis). Table 1 details the definition of lobe-specific mediastinal nodes according to respective involved pulmonary lobes. Any positive mediastinal nodes beyond this range were deemed non-lobe-specific metastasis.
Follow-up
Follow-up was routinely performed on patients once every 3 months for the first 2 years after operation and every six months thereafter. Telephone interviews, or direct outpatient clinic consultation was offered to each subject. Information for survival and cause of death was collected by a trained staff member of our department. The end-point of follow-up was April 2012 or date of death.
Statistical analysis
Continuous variables were expressed as mean ± SD (standard deviation). Chi-square test was for categorical variables, and the student's t-test was for continuous variables. The survival rate was calculated using the KaplanMeier and the life-table methods. Differences among survival rates were compared using the log-rank test. The Cox regression model was performed for multivariate analysis. Relative risk and 95% confidence intervals were calculated. The p values <0.05 were considered to be statistically significant, and all statistical analysis was performed on SPSS version 17.0 software.
Results

General information
The present case series included 437 (66.8%) males and 217 (33.2%) females, with an average age of 58.18 ± 9.70 years (range: 25-86). Among the total patients, 569 (87.0%) were under 70 years of age; 85 (13.0%) patients were older than or equal to 70. The tumor was located at the right side in 390 cases and in 264 at the left. There were 206, 46, and 123 cases at the rightupper, -middle, and -lower lobes, respectively, and 15 at the right-middle-lower lobes; there were 160 left-upper lobes and 104 left-lower lobes involved. A total of 104 pneumonectomies, 400 lobectomies, 63 bilobectomies, and 83 extended lobectomies (31 sleeve lobectomies, 52 angioplastic, or bronchoplastic operations) were performed. Moreover, partial atrium resection was performed on three cases and tangential SVC resection for one case. Coexisting diseases, including hypertension, diabetes, coronary heart disease, obstructive pneumonia, gastric ulcer, bronchiectasis, emphysema, and arthritis were reported in 136 patients.
Complications
Postoperative complications occurred in 24 cases. Six patients underwent re-operation because of excessive bleeding (3 cases), chylothorax (2 cases), and bronchopleural fistula (1 case). Acute pulmonary embolisms were radiologically confirmed in a lobectomy case and were eventually resolved after a two-week anticoagulant administration. The other complications included prolonged air leakage in eight patients (>2 weeks), pulmonary infection which required prolonged medical intervention (five cases), empyema (two cases), and atrial fibrillation in two cases. There were no perioperative deaths.
Histopathologic information
Histology confirmed 312 (47.7%) adenocarcinomas, 194 (29.7%) squamous cell carcinomas, 140 (21.4%) adenosquamous carcinomas, and 8 (1.87%) large cell carcinomas. 107 cases were staged at T1, 457 at T2, 60 at T3 and 30 at T4, respectively, and the average tumor size was 4.10 ± 1.92 cm. A total of 9081 lymph nodes (6172 mediastinal and 2909 intra-parenchymal or hilar LNs) had been removed, at an average of 13.9 ± 7.41 nodes per patient. 2789 mediastinal nodes were pathologically positive among the removed mediastinal nodes. According to the prior definitions (Table 1) , the mediastinal lymph-nodes metastasis were limited to the lobespecific region in 376 cases, while it was beyond this borderline in the rest of the 278 cases.
Clinical features of Groups LS and NLS
There were 376 cases in Group LS and 278 in Group NLS. In the LS group, there were 50 cases at T1, 280 at T2, 32 at T3, and 14 at T4. In addition, there were 57 cases at T1, 177 at T2, 28 at T3, and 16 at T4 in the NLS group. The total number of resected lymph nodes was 5167 in the LS group and 3914 in the NLS group, and the number of positive mediastinal nodes was 1063 in the LS group and 1726 in NLS group. Clinical characteristics of the two groups are detailed in Table 2 and Fig. 1A .
Follow-up information
Follow-up information was obtained in 589 cases, with a 90.06% follow-up rate. The mean follow-up period was 28.09 months (range: 6-79 months). All patients received four cycles of cisplatin-based chemotherapies. Adjuvant mediastinal radiotherapies at 50-54 Gy/5 weeks were administered to 104 patients. By the time of the final follow-up, 334 patients (51.07%) had died; remote metastasis and cancer relapse were the cause of death in 272 cases.
Survival comparison between Groups LS and NLS
The overall 5-year survival rate was 20.8% for the whole patient cohort, with a median survival time (MST) of 31 (95% CI 28.3-33.7) months (Fig. 1B) . Group NLS has a significantly worse 5-year survival rate in comparison with Group LS (11.7% vs. 27.5%); the MST was 24 (95% CI 19.7-28.3) months and 37 (95% CI 33.4-40.6) months for these two groups, respectively (Fig. 1C) .
Risk factors of survival under univariate analysis
Univariate analysis showed that the risk factors of the 5-year survival included operation types, MLN positivity ratio, the number of involved MLNs stations, nodal zones, and the grouping method of LS/NLS metastasis ( Table 3 ; Fig. 1D-1G ).
Grouping of LS/NLS is an independent risk factor in 5-year survival
Multivariate analysis using Cox regression revealed that the number of involved nodal zones and LS/NLS metastasis were independent risk factors for cancerrelated survival ( Table 4 ). The rest of the variables, including number of involved stations, age, gender, tumor location, tumor size, pathologic type, MLN positive ratio, pT-stage, operation type, number of MLNs resection, and number of MLNs positive, were not independent risk factors. Group NLS was associated with a worse prognosis; the relative risk for cancer-related death was 1.381 times that of Group LS.
Discussion
The concept of lobe-specific nodes had been adopted to describe the special phenomenon that lymphatic drainage of cancer cells generally follows a fixed route. Specifically, the upper mediastinal region has the priority for drainage of the upper lobes and tumor cells from the lower lobes, usually preceding inferior mediastinal regions other than the superior area. Such findings have also led to the practice of selective lymph node dissection for early-stage lung cancer cases thereafter. The 5-year survival after lobe-specific nodal removal was around 76%, which was comparable to that after a widerrange lymphatic dissection (5-year survival at 71.9%). 5) However, for advanced non-small cell lung cancers, the prognostic significance of lobe-specific nodes has remained unclear. Additionally, the topic also requires further clarification regarding whether selective lymphadenectomy, based on the concept of lobe-specific nodes, could be applied to N2 candidates. According to our findings, the metastatic status of non-lobe-specific nodes is an independent prognostic risk factor for stage III-N2 cases. The median survival time of Group NLS (nodal metastasis beyond lobespecific nodes) was only 24 months, and the 5-year survival rate was 11.7%, both of which were much worse than those of Group LS (nodal metastasis limited to lobe-specific nodes) (p <0.0001). The underlying mechanism may lie in that Group NLS represents extensive spreading of tumor cells along the mediastinal lymph network. Previous works of literature had elsewhere documented comparable findings concerning the range of mediastinal nodal involvement and patients' survival. Most related concepts included "highest mediastinal lymph nodes," "ratio of positive nodes," and "number of involved nodal zones/stations." Dr. Zheng 12) noted that the highest nodal involvement predicted very poor longterm survival from the whole, with the 5-year survival rate and median survival time (MST) being only 13% and 24.43 months. However, they were prominently better (29% and 36.48 months) when the highest nodes were negative (p <0.001). Nwogu, et al. 13 ) also determined Fig. 1 (A) Shows the scope of mediastinal nodal involvement in the two study groups. In Group LS, 60.8% cases had one-station metastasis (LS: 60.8% vs. NLS: 18.7%, p <0.05), while 30.9% had 3-station involvement in Group NLS (LS: 9.6% vs. NLS: 30.9%, p <0.05). This phenomenon highly suggested that the nodal metastasis beyond the lobe-specific nodes was usually associated with more extensive lymphatic spread. *Significant difference with p <0.05. (B) Shows the overall survival of present patient cohort by life table. (C) Shows the significant survival difference between Groups LS and NLS. In addition to the Groups LS/NLS, survival difference was also significant between cases with different operation types (D). The survival difference was significant between cases with different MLN positive ratios, with single or multiple stations involvement (E, F), and with single or multiple nodal zones metastasis (G). LS: lobe-specific; NLS: non-lobe-specific; 5YS: 5-year survival; MST: median survival time; MLN: mediastinal lymph node
that lower and moderate ratios of positive LNs were associated with better overall survival than those with high ratios (more than 50%) in lymph-node-positive NSCLC patients. In addition, the number of involved nodal stations also had a prognostic role: The 5-year overall survival rate was 34% when only a single station was involved, while it was 11% for those with multiple stations (p <0.001). 14) Similarly, single nodal zone involvement In addition, the status of non-lobe-specific lymph nodes may have potential utilization for future sub-grouping of stage N2-IIIa patient cohorts. There are currently three categorizing systems for the N2 disease. One method is to categorize four grades by conditions of mediastinal nodal stations: incidentally intra-operatively found nodal metastases at a single station, preoperative confirmed single station metastasis, multiple stations metastasis, and bulky or fixed multi-station N2 disease. 14) The second method involves differentiating by numbers of involved nodal zones, whether single or multiple zonal involvements. 2) The third method was suggested by Riquet, et al. 16) : single and multiple mediastinal nodal chains involvement. Although each of these three methods actually delineates the extent of lymphatic spread, none had incorporated the concept of lobe-specific nodes into the system. Considering that it is an independent prognostic factor, the future combination of all of the above risk factors may provide us a more accurate method of outcome prediction.
It was not surprising that, in advanced stage lung cancers, mediastinal lymph nodes were commonly more involved than lobe-specific nodes. Watanabe, et al. 4) noted that about half of the right middle/lower lobe NSCLC had nodal metastases to the upper mediastinum; nodal metastases to the lower mediastinum from upper lobe primary lesions were found in one-third of cases. Saeteng 17) also documented that 40% of lower lobes (RLL and LLL) had nodal metastasis to the upper mediastinal lymph node and 20% of upper lobes (RUL and LUL) had nodal metastasis to the lower mediastinal lymph node. The metastatic rate of nodal dissemination was comparable (42.5%) in the present study. Group LS showed more cases of single station involvement and less incidence of multiple station metastases. Such a phenomenon suggested again that there was wide and complex communication in the mediastinal lymphatic web, and this therefore strongly advocates the necessity of radical systemic nodal dissection for N2-IIIa patients. The method of selective lymph node dissection, although seemingly provocative for early stage lung cancers, was however unsuitable for cancers at advanced stages.
Conclusion
Lymph node metastasis beyond lobe-specific lymph nodes (defined as non-lobe-specific nodes in the present study) in stage pN2-III patient cohorts was associated with only 11% cases of five-year survival rate. The condition of non-lobe-specific nodes involvement is an independent risk factor of worse prognoses for stage pN2-III NSCLC patients.
